Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Место современных фторхинолонов в терапии интраабдоминальных инфекций и инфекций малого таза
Место современных фторхинолонов в терапии интраабдоминальных инфекций и инфекций малого таза
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Перитонит. Практическое руководство. Под ред. В.С.Савельева, Б.Р.Гельфанда, М.И.Филимоновой. М., 2006.
2. Andersson MI, MacGowan AP. Development of quinolones. J Antimicrob Chemother 2003; 51 (Suppl. Sl): 1–11.
3. Holzheimer RG, Dralle H. Antibiotic therapy in intra-abdominal infections. A review on randomised clinical trials. Eur J Med Res 2001; 6: 277–91.
4. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997–1005.
5. Takahashi H, Hayakawa I, Akimoto T. The history of the development and changes of guinolone antibacterial agents. Yakushigaku Zasahi 2003; 38 (2): 161–79.
6. Hooper DC. Quinolones. In: Principles and Practice of infections Diseases. Mandel, Douglas, Bennett's. 1999; 451–69.
7. Blondean JM, Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opin Pharmacother 2004; 5: 1117–52.
8. Keating GM, Scott LJ. Moxifloxacin. A review of its use in the management of bacterial infections. Drugs 2004; 64 (20): 2347–77.
9. Behra-Miellet J, Dubreui A, Jumas-Bilak E. Antianaerobic activity of moxifloxacim campared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. Int J Antimicrob Agents 2002; 20 (5): 366–74.
10. Kim MM-R, Nightingale CH. Pharmacokinetics and pharmacodinamics of the fluoroquinolones. In: The Quinolones. Andriole VT, ed. San Diego: Academic Press 2000; 169–202.
11. Stass H, Rink AD, Delesen H et al. Pharmacocinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58 (3): 693–6.
12. Wacke R, Forster S, Adam U et al. Penetration of moxifloxacin intо the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 2006; 58 (5): 994–9.
13. Яковлев В.П., Яковлев С.В. Возможности профилактического и лечебного применения левофлоксацина. Consilium Medicum 2002; 4.
14. Крескен М., Лоде Х. Фторхинолоном какого поколения следует считать левофлоксацин. КМАХ. 2005; 7 (3): 298–305.
15. Simpson I, Jones N. Intern J Antimicrob 2001; 17 (Suppl. I): аbstr NP 20.009.
16. Hooper DC. New uses for new and old quinolones and the challenge of resistence. Clin Infect Dis 2000; 30: 243–54.
17. Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med Lett Drugs Ther 2000; 42: 15–7.
18. Stein EG, Goldstein EJ. Fluoroquinolones and anaerobes. Clin Infect Dis 2006; 42: 1598–607.
19. Malangoni NM et al. Randomized controlled trial of moxifloxacin compared with piperacillin/tazobactam and amoxicillin/clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006; 244: 204–11.
20. Ross JDC, Cronje HS, Rakoczi I et al. Моксифлоксацин в сравнении с комбинацией офлоксацин/метронидазол при НВЗОМТ: результаты КИ. Материалы XVI Международного общества по изучению болезней, передающихся половым путем, ISSTDR. Амстердам. 10–13 июля 2005.
21. Heystek M, Tellarini M, Schmitz H et al. Efficacy and safety of moxifloxacin vs ciprofloxacint plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemoter 1999; 44 (Suppl. A): 143.
22. Зайцев А.А., Карпов О.И., Стрекачев А.Ю. Новые возможности антибактериальной терапии инфекций в хирургической практике. Антибиот. и химиотер. 2003; 48: 5.
2. Andersson MI, MacGowan AP. Development of quinolones. J Antimicrob Chemother 2003; 51 (Suppl. Sl): 1–11.
3. Holzheimer RG, Dralle H. Antibiotic therapy in intra-abdominal infections. A review on randomised clinical trials. Eur J Med Res 2001; 6: 277–91.
4. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997–1005.
5. Takahashi H, Hayakawa I, Akimoto T. The history of the development and changes of guinolone antibacterial agents. Yakushigaku Zasahi 2003; 38 (2): 161–79.
6. Hooper DC. Quinolones. In: Principles and Practice of infections Diseases. Mandel, Douglas, Bennett's. 1999; 451–69.
7. Blondean JM, Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opin Pharmacother 2004; 5: 1117–52.
8. Keating GM, Scott LJ. Moxifloxacin. A review of its use in the management of bacterial infections. Drugs 2004; 64 (20): 2347–77.
9. Behra-Miellet J, Dubreui A, Jumas-Bilak E. Antianaerobic activity of moxifloxacim campared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. Int J Antimicrob Agents 2002; 20 (5): 366–74.
10. Kim MM-R, Nightingale CH. Pharmacokinetics and pharmacodinamics of the fluoroquinolones. In: The Quinolones. Andriole VT, ed. San Diego: Academic Press 2000; 169–202.
11. Stass H, Rink AD, Delesen H et al. Pharmacocinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58 (3): 693–6.
12. Wacke R, Forster S, Adam U et al. Penetration of moxifloxacin intо the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 2006; 58 (5): 994–9.
13. Яковлев В.П., Яковлев С.В. Возможности профилактического и лечебного применения левофлоксацина. Consilium Medicum 2002; 4.
14. Крескен М., Лоде Х. Фторхинолоном какого поколения следует считать левофлоксацин. КМАХ. 2005; 7 (3): 298–305.
15. Simpson I, Jones N. Intern J Antimicrob 2001; 17 (Suppl. I): аbstr NP 20.009.
16. Hooper DC. New uses for new and old quinolones and the challenge of resistence. Clin Infect Dis 2000; 30: 243–54.
17. Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med Lett Drugs Ther 2000; 42: 15–7.
18. Stein EG, Goldstein EJ. Fluoroquinolones and anaerobes. Clin Infect Dis 2006; 42: 1598–607.
19. Malangoni NM et al. Randomized controlled trial of moxifloxacin compared with piperacillin/tazobactam and amoxicillin/clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006; 244: 204–11.
20. Ross JDC, Cronje HS, Rakoczi I et al. Моксифлоксацин в сравнении с комбинацией офлоксацин/метронидазол при НВЗОМТ: результаты КИ. Материалы XVI Международного общества по изучению болезней, передающихся половым путем, ISSTDR. Амстердам. 10–13 июля 2005.
21. Heystek M, Tellarini M, Schmitz H et al. Efficacy and safety of moxifloxacin vs ciprofloxacint plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemoter 1999; 44 (Suppl. A): 143.
22. Зайцев А.А., Карпов О.И., Стрекачев А.Ю. Новые возможности антибактериальной терапии инфекций в хирургической практике. Антибиот. и химиотер. 2003; 48: 5.
2. Andersson MI, MacGowan AP. Development of quinolones. J Antimicrob Chemother 2003; 51 (Suppl. Sl): 1–11.
3. Holzheimer RG, Dralle H. Antibiotic therapy in intra-abdominal infections. A review on randomised clinical trials. Eur J Med Res 2001; 6: 277–91.
4. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997–1005.
5. Takahashi H, Hayakawa I, Akimoto T. The history of the development and changes of guinolone antibacterial agents. Yakushigaku Zasahi 2003; 38 (2): 161–79.
6. Hooper DC. Quinolones. In: Principles and Practice of infections Diseases. Mandel, Douglas, Bennett's. 1999; 451–69.
7. Blondean JM, Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opin Pharmacother 2004; 5: 1117–52.
8. Keating GM, Scott LJ. Moxifloxacin. A review of its use in the management of bacterial infections. Drugs 2004; 64 (20): 2347–77.
9. Behra-Miellet J, Dubreui A, Jumas-Bilak E. Antianaerobic activity of moxifloxacim campared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. Int J Antimicrob Agents 2002; 20 (5): 366–74.
10. Kim MM-R, Nightingale CH. Pharmacokinetics and pharmacodinamics of the fluoroquinolones. In: The Quinolones. Andriole VT, ed. San Diego: Academic Press 2000; 169–202.
11. Stass H, Rink AD, Delesen H et al. Pharmacocinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58 (3): 693–6.
12. Wacke R, Forster S, Adam U et al. Penetration of moxifloxacin intо the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 2006; 58 (5): 994–9.
13. Яковлев В.П., Яковлев С.В. Возможности профилактического и лечебного применения левофлоксацина. Consilium Medicum 2002; 4.
14. Крескен М., Лоде Х. Фторхинолоном какого поколения следует считать левофлоксацин. КМАХ. 2005; 7 (3): 298–305.
15. Simpson I, Jones N. Intern J Antimicrob 2001; 17 (Suppl. I): аbstr NP 20.009.
16. Hooper DC. New uses for new and old quinolones and the challenge of resistence. Clin Infect Dis 2000; 30: 243–54.
17. Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med Lett Drugs Ther 2000; 42: 15–7.
18. Stein EG, Goldstein EJ. Fluoroquinolones and anaerobes. Clin Infect Dis 2006; 42: 1598–607.
19. Malangoni NM et al. Randomized controlled trial of moxifloxacin compared with piperacillin/tazobactam and amoxicillin/clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006; 244: 204–11.
20. Ross JDC, Cronje HS, Rakoczi I et al. Моксифлоксацин в сравнении с комбинацией офлоксацин/метронидазол при НВЗОМТ: результаты КИ. Материалы XVI Международного общества по изучению болезней, передающихся половым путем, ISSTDR. Амстердам. 10–13 июля 2005.
21. Heystek M, Tellarini M, Schmitz H et al. Efficacy and safety of moxifloxacin vs ciprofloxacint plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemoter 1999; 44 (Suppl. A): 143.
22. Зайцев А.А., Карпов О.И., Стрекачев А.Ю. Новые возможности антибактериальной терапии инфекций в хирургической практике. Антибиот. и химиотер. 2003; 48: 5.
________________________________________________
2. Andersson MI, MacGowan AP. Development of quinolones. J Antimicrob Chemother 2003; 51 (Suppl. Sl): 1–11.
3. Holzheimer RG, Dralle H. Antibiotic therapy in intra-abdominal infections. A review on randomised clinical trials. Eur J Med Res 2001; 6: 277–91.
4. Solomkin JS, Mazuski JE, Baron EJ et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997–1005.
5. Takahashi H, Hayakawa I, Akimoto T. The history of the development and changes of guinolone antibacterial agents. Yakushigaku Zasahi 2003; 38 (2): 161–79.
6. Hooper DC. Quinolones. In: Principles and Practice of infections Diseases. Mandel, Douglas, Bennett's. 1999; 451–69.
7. Blondean JM, Missaghi B. Gemifloxacin: a new fluoroquinolone. Expert Opin Pharmacother 2004; 5: 1117–52.
8. Keating GM, Scott LJ. Moxifloxacin. A review of its use in the management of bacterial infections. Drugs 2004; 64 (20): 2347–77.
9. Behra-Miellet J, Dubreui A, Jumas-Bilak E. Antianaerobic activity of moxifloxacim campared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. Int J Antimicrob Agents 2002; 20 (5): 366–74.
10. Kim MM-R, Nightingale CH. Pharmacokinetics and pharmacodinamics of the fluoroquinolones. In: The Quinolones. Andriole VT, ed. San Diego: Academic Press 2000; 169–202.
11. Stass H, Rink AD, Delesen H et al. Pharmacocinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58 (3): 693–6.
12. Wacke R, Forster S, Adam U et al. Penetration of moxifloxacin intо the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 2006; 58 (5): 994–9.
13. Яковлев В.П., Яковлев С.В. Возможности профилактического и лечебного применения левофлоксацина. Consilium Medicum 2002; 4.
14. Крескен М., Лоде Х. Фторхинолоном какого поколения следует считать левофлоксацин. КМАХ. 2005; 7 (3): 298–305.
15. Simpson I, Jones N. Intern J Antimicrob 2001; 17 (Suppl. I): аbstr NP 20.009.
16. Hooper DC. New uses for new and old quinolones and the challenge of resistence. Clin Infect Dis 2000; 30: 243–54.
17. Gatifloxacin and moxifloxacin: two new fluoroquinolones. Med Lett Drugs Ther 2000; 42: 15–7.
18. Stein EG, Goldstein EJ. Fluoroquinolones and anaerobes. Clin Infect Dis 2006; 42: 1598–607.
19. Malangoni NM et al. Randomized controlled trial of moxifloxacin compared with piperacillin/tazobactam and amoxicillin/clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006; 244: 204–11.
20. Ross JDC, Cronje HS, Rakoczi I et al. Моксифлоксацин в сравнении с комбинацией офлоксацин/метронидазол при НВЗОМТ: результаты КИ. Материалы XVI Международного общества по изучению болезней, передающихся половым путем, ISSTDR. Амстердам. 10–13 июля 2005.
21. Heystek M, Tellarini M, Schmitz H et al. Efficacy and safety of moxifloxacin vs ciprofloxacint plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemoter 1999; 44 (Suppl. A): 143.
22. Зайцев А.А., Карпов О.И., Стрекачев А.Ю. Новые возможности антибактериальной терапии инфекций в хирургической практике. Антибиот. и химиотер. 2003; 48: 5.
Авторы
А.П.Зузова
Кафедра клинической фармакологии СГМА, Смоленск
Кафедра клинической фармакологии СГМА, Смоленск
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.